BioCentury
ARTICLE | Clinical News

MAT2501: Ph I data

March 31, 2017 5:14 AM UTC

Top-line data from a double-blind, placebo-controlled Phase I trial in 36 healthy volunteers showed that single ascending doses of oral MAT2501 were well tolerated with no serious adverse events repor...

BCIQ Company Profiles

Matinas BioPharma Holdings Inc.

BCIQ Target Profiles

Ergosterol